{
}
Merck & Co. has acquired Modifi Biosciences for $30 million, with potential additional payments of up to $1.3 billion based on milestones. Meanwhile, Roche reported that sales of Sarepta's gene therapy Elevidys reached approximately $156 million outside the U.S. in the first nine months of the year. Sangamo Therapeutics is on track to file for accelerated approval of its Fabry disease treatment, while MacroGenics sold rights to its breast cancer drug Margenza for $40 million, with additional milestone payments possible.
Alessandro Maselli
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
merck acquires cancer startup elevidys sales rise and other industry updates
United States Dollar
Swiss Franc
Hoffmann-La Roche AG
Merck & Co., Inc.
UCB SA
Sarepta Therapeutics, Inc.
Sangamo Therapeutics, Inc.
Ned Pagliarulo
Delilah Alvarado
Jonathan Gardner
Alessandro Maselli
Show more
17:45 23.10.2024
Trending
Subcategory
Corporate News
Startups & Entrepreneurship
Venture Capital Investments
Industry Trends
Cryptocurrency Trends
Fintech Startups
Emerging Startups
Funding Rounds & Investments
AI Innovations
Retail and Consumer Goods
Crypto Policies and Governance
Crypto Adoption and Integration
IPOs & SPACs
Economic Indicators
Product Launches
Market Analysis and Predictions
Stock Market Updates
IPOs of Tech Companies
AI Applications
Finance Mergers & Acquisitions
Countries:
Companies:
Nvidia Corporation
Microsoft Corporation Corp.
Amazon.com Inc.
Alphabet Inc.
Apple Inc.
DEUTSCHE BANK AG
Micelio Technology Fund 1
PayPal Holdings Inc.
Uber Technologies Inc.
Indifi Technologies Ltd.
The Goldman Sachs Group, Inc.
Axis Capital Ltd.
UBS Group AG
Reddit Inc.
Google LLC
Anduril Industries Inc.
Maruishi Pharmaceutical Co. Ltd.
Qatar Islamic Bank ش.م.ع
Walmart Inc.
Trump Media & Technology Group Corp.
Currencies:
People: